Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized Comprehensive Treatment After Standard Treatment for Advanced Hepatocellular Carcinoma
NCT06893887Recruiting
- Sponsor
- Nanjing Tianyinshan Hospital
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Bispecific Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label trial of oxaliplatin + fluorouracil + leucovorin, adebrelimab, Rivoceranib, Icaritin, retlirafusp alfa and 2 more in hepatocellular carcinoma (HCC) (9 arms), sponsored by Nanjing Tianyinshan Hospital. Primary endpoint: Progression-free Survival at 24 months. Started May 2025; status: recruiting.
02
Drugs
oxaliplatin + fluorouracil + leucovorinadebrelimabRivoceranibIcaritinretlirafusp alfa
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06893887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06893887.